Literature DB >> 30975760

Mutations in the HIV-1 envelope glycoprotein can broadly rescue blocks at multiple steps in the virus replication cycle.

Rachel Van Duyne1, Lillian S Kuo1, Phuong Pham1, Ken Fujii1, Eric O Freed2.   

Abstract

The p6 domain of HIV-1 Gag contains highly conserved peptide motifs that recruit host machinery to sites of virus assembly, thereby promoting particle release from the infected cell. We previously reported that mutations in the YPXnL motif of p6, which binds the host protein Alix, severely impair HIV-1 replication. Propagation of the p6-Alix binding site mutants in the Jurkat T cell line led to the emergence of viral revertants containing compensatory mutations not in Gag but in Vpu and the envelope (Env) glycoprotein subunits gp120 and gp41. The Env compensatory mutants replicate in Jurkat T cells and primary human peripheral blood mononuclear cells, despite exhibiting severe defects in cell-free particle infectivity and Env-mediated fusogenicity. Remarkably, the Env compensatory mutants can also rescue a replication-delayed integrase (IN) mutant, and exhibit reduced sensitivity to the IN inhibitor Dolutegravir (DTG), demonstrating that they confer a global replication advantage. In addition, confirming the ability of Env mutants to confer escape from DTG, we performed de novo selection for DTG resistance and observed resistance mutations in Env. These results identify amino acid substitutions in Env that confer broad escape from defects in virus replication imposed by either mutations in the HIV-1 genome or by an antiretroviral inhibitor. We attribute this phenotype to the ability of the Env mutants to mediate highly efficient cell-to-cell transmission, resulting in an increase in the multiplicity of infection. These findings have broad implications for our understanding of Env function and the evolution of HIV-1 drug resistance.

Entities:  

Keywords:  Dolutegravir; cell–cell transmission; drug resistance; virological synapse

Year:  2019        PMID: 30975760      PMCID: PMC6500141          DOI: 10.1073/pnas.1820333116

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  98 in total

1.  Structure-function studies of the self-assembly domain of the human immunodeficiency virus type 1 transmembrane protein gp41.

Authors:  Y Weng; Z Yang; C D Weiss
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

2.  The long cytoplasmic tail of gp41 is required in a cell type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions.

Authors:  T Murakami; E O Freed
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

3.  An in vitro rapid-turnover assay for human immunodeficiency virus type 1 replication selects for cell-to-cell spread of virus.

Authors:  S Gummuluru; C M Kinsey; M Emerman
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

4.  HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress.

Authors:  J Martin-Serrano; T Zang; P D Bieniasz
Journal:  Nat Med       Date:  2001-12       Impact factor: 53.440

Review 5.  Directed egress of animal viruses promotes cell-to-cell spread.

Authors:  David C Johnson; Mary T Huber
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

6.  Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding.

Authors:  J E Garrus; U K von Schwedler; O W Pornillos; S G Morham; K H Zavitz; H E Wang; D A Wettstein; K M Stray; M Côté; R L Rich; D G Myszka; W I Sundquist
Journal:  Cell       Date:  2001-10-05       Impact factor: 41.582

7.  Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens.

Authors:  D V Havlir; N S Hellmann; C J Petropoulos; J M Whitcomb; A C Collier; M S Hirsch; P Tebas; J P Sommadossi; D D Richman
Journal:  JAMA       Date:  2000-01-12       Impact factor: 56.272

8.  HIV-1 evolves into a nonsyncytium-inducing virus upon prolonged culture in vitro.

Authors:  A T Das; A Land; I Braakman; B Klaver; B Berkhout
Journal:  Virology       Date:  1999-10-10       Impact factor: 3.616

9.  Drug resistance in patients experiencing early virological failure under a triple combination including indinavir.

Authors:  O Gallego; C de Mendoza; M J Pérez-Elías; J M Guardiola; J Pedreira; D Dalmau; J Gónzalez; A Moreno; J R Arribas; A Rubio; I García-Arata; M Leal; P Domingo; V Soriano
Journal:  AIDS       Date:  2001-09-07       Impact factor: 4.177

10.  Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55(Gag).

Authors:  L VerPlank; F Bouamr; T J LaGrassa; B Agresta; A Kikonyogo; J Leis; C A Carter
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-26       Impact factor: 11.205

View more
  19 in total

Review 1.  Multifaceted HIV integrase functionalities and therapeutic strategies for their inhibition.

Authors:  Alan N Engelman
Journal:  J Biol Chem       Date:  2019-08-29       Impact factor: 5.157

2.  Short Communication: HIV-DRLink: A Tool for Reporting Linked HIV-1 Drug Resistance Mutations in Large Single-Genome Data Sets Using the Stanford HIV Database.

Authors:  Wei Shao; Valerie F Boltz; Junko Hattori; Michael J Bale; Frank Maldarelli; John M Coffin; Mary F Kearney
Journal:  AIDS Res Hum Retroviruses       Date:  2020-08-27       Impact factor: 2.205

Review 3.  Molecular adaptations during viral epidemics.

Authors:  Nash D Rochman; Yuri I Wolf; Eugene V Koonin
Journal:  EMBO Rep       Date:  2022-07-18       Impact factor: 9.071

4.  Mutations in the HIV-1 3'-Polypurine Tract Can Confer Dolutegravir Resistance.

Authors:  José G Dekker; Bep Klaver; Ben Berkhout; Atze T Das
Journal:  Antimicrob Agents Chemother       Date:  2021-10-11       Impact factor: 5.938

Review 5.  A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection.

Authors:  Alexa Vyain Zhao; Rustin D Crutchley; Rakesh Chowdary Guduru; Kathy Ton; Tammie Lam; Amy Cheng Min
Journal:  Retrovirology       Date:  2022-10-22       Impact factor: 3.768

6.  Elucidating the Basis for Permissivity of the MT-4 T-Cell Line to Replication of an HIV-1 Mutant Lacking the gp41 Cytoplasmic Tail.

Authors:  Melissa V Fernandez; Huxley K Hoffman; Nairi Pezeshkian; Philip R Tedbury; Schuyler B van Engelenburg; Eric O Freed
Journal:  J Virol       Date:  2020-11-09       Impact factor: 5.103

Review 7.  Recent Advances in the Development of Integrase Inhibitors for HIV Treatment.

Authors:  Jay Trivedi; Dinesh Mahajan; Russell J Jaffe; Arpan Acharya; Debashis Mitra; Siddappa N Byrareddy
Journal:  Curr HIV/AIDS Rep       Date:  2020-02       Impact factor: 5.071

8.  A systematic review of the genetic mechanisms of dolutegravir resistance.

Authors:  Soo-Yon Rhee; Philip M Grant; Philip L Tzou; Geoffrey Barrow; P Richard Harrigan; John P A Ioannidis; Robert W Shafer
Journal:  J Antimicrob Chemother       Date:  2019-11-01       Impact factor: 5.790

9.  Gp41-targeted antibodies restore infectivity of a fusion-deficient HIV-1 envelope glycoprotein.

Authors:  Vinita R Joshi; Ruchi M Newman; Melissa L Pack; Karen A Power; James B Munro; Ken Okawa; Navid Madani; Joseph G Sodroski; Aaron G Schmidt; Todd M Allen
Journal:  PLoS Pathog       Date:  2020-05-11       Impact factor: 6.823

10.  EWI-2 Inhibits Cell-Cell Fusion at the HIV-1 Virological Presynapse.

Authors:  Emily E Whitaker; Nicholas J Matheson; Sarah Perlee; Phillip B Munson; Menelaos Symeonides; Markus Thali
Journal:  Viruses       Date:  2019-11-20       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.